DNP Dai Nippon Printing Co., Ltd. has acquired KYOWA HAKKO BIO ITALIA S.r.l. for an undisclosed amount. This corporate acquisition marks a strategic expansion for DNP into the health ingredients sector. KYOWA HAKKO BIO ITALIA S.r.l. serves as the dedicated sales office for KYOWA HAKKO BIO CO., LTD. across the EMEA territory, and also functions as a distributor for Kyowa Pharma Chemical Co.
KYOWA HAKKO BIO ITALIA is recognized as an international health ingredients manufacturer and a prominent entity in the development, manufacturing, and marketing of nutraceuticals and pharmaceutical products. The company has established itself as a pioneer in fermentation technology, maintaining a commitment to ongoing research, developing innovative new products, and upholding stringent quality management standards. Its portfolio includes well-known branded ingredients such as Setria® Glutathione, Cognizin® Citicoline, and EYEMUSE™ Lacticaseibacillus paracasei KW3110.
The acquisition is strategically significant for DNP, enabling the company to enhance its footprint within the growing health and wellness market. By integrating KYOWA HAKKO BIO ITALIA's established sales network and specialized product offerings, DNP aims to strengthen its capabilities in the functional ingredients segment. This move provides DNP with direct access to KYOWA HAKKO BIO ITALIA's expertise in advanced fermentation technology and its portfolio of high-value nutraceutical and pharmaceutical ingredients.
Expected synergies from this acquisition include leveraging KYOWA HAKKO BIO ITALIA's deep market knowledge and customer relationships across EMEA, combined with DNP's broader corporate resources. The integration is anticipated to facilitate expanded distribution channels and accelerate the introduction of innovative health-focused solutions. The combined entity is positioned to reinforce its market presence and drive further growth in the global health ingredients industry.